Q1

Strong start
to the year
for Bayer

Quarterly Review

Very good business development at Pharmaceuticals

Growth momentum across all segments

Group outlook for 2017 raised, driven by Covestro performance
Core earnings per share
€2.62 (+11.5%)
Group sales
€13.2 billion (+9.4%)
Download Full Report (PDF, 0.5MB) Bayer Newsletter Investor Conference Call Share

Selected Key Figures

  • Sales

    Key figure Sales (bar chart)Key figure Sales (bar chart) Inactive key figure Sales (bar chart)Inactive key figure Sales (bar chart)

  • EBITDA Before Special Items

    Key figure EBITDA margin (bar chart)Key figure EBITDA margin (bar chart) Inactive key figure EBITDA margin (bar chart)Inactive key figure EBITDA margin (bar chart)

  • Net income

    Inactive key figure Net income (bar chart)Inactive key figure Net income (bar chart) Key figure Net income (bar chart)Key figure Net income (bar chart)

+9.4%

In the first quarter, sales increased by 9.4 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.) to €13.2 billion.

View all Q1 key figures

+14.9%

Group EBITDA before special items increased by 14.9 percent to €3,893 million.

View all Q1 key figures

+37.9%

After income tax expense of €595 million (Q1 2016: €474 million) and adjusting for income from discontinued operations after income taxes and noncontrolling interest, net income for the first quarter of 2017 amounted to €2,083 million (Q1 2016: €1,511 million).

View all Q1 key figures

Business Development of the Divisions

Pharmaceuticals

Our Pharmaceuticals business expanded in all regions on a currency-adjusted basis. Sales of Pharmaceuticals rose by an encouraging 7.4 percent (Fx & portfolio adj.) to €4,263 million in the first quarter of 2017. Our key growth products once again delivered strong performance, with their combined sales rising by 20.0 percent (Fx adj.) to €1,445 million (Q1 2016: €1,187 million).

Find out more

Consumer Health

Sales of Consumer Health rose by 2.6 percent (Fx & portfolio adj.) in the first quarter of 2017 to €1,601 million. We registered encouraging growth in Europe / Middle East / Africa and Asia Pacific. Sales in North America were level year on year on a currency-adjusted basis, while business declined substantially in Latin America.

Find out more

Crop Science

In the first quarter of 2017, Crop Science posted sales of €3,120 million (Fx & portfolio adj. + 3.2 percent). Growth at Crop Protection / Seeds was largely due to encouraging performance in North America. The sales growth recorded at Environmental Science was based on the delivery of products to the company that acquired our consumer business.

Find out more